Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)), Erlangen, Germany.
CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Front Immunol. 2024 Oct 14;15:1478196. doi: 10.3389/fimmu.2024.1478196. eCollection 2024.
Urothelial bladder cancer is frequent and exhibits diverse prognoses influenced by molecular subtypes, urothelial subtype histology, and immune microenvironments. HLA-G, known for immune regulation, displays significant membranous expression in tumor tissues.
We studied the protein expression of Human Leucocyte Antigen G (HLA-G) in 241 Muscle-Invasive Bladder Cancer (MIBC) patients, elucidating its potential clinical and biological significance. Protein expression levels were evaluated and correlated with molecular subtypes, histological characteristics, immune microenvironment markers, and survival outcomes.
High HLA-G expression associates with poor overall survival (OS) and diseasespecific survival (DSS), independent of clinicopathological parameters. HLA-G expression varies among molecular subtypes and Urothelial Subtype Histology, e.g., elevated expression levels in basal/squamous MIBC and those with sarcomatoid differentiation. Notably, HLA-G is increased in MIBC with an immune evasive microenvironment (high PD-L1 tumor cell expression, NK cell depletion, granzyme B (GZMB)/CD8 ratio reduction, MHC class I (MHCI) expression reduction) that are characterized by immunosuppressive features and poor prognosis. Furthermore, HLA-G correlates with elevated levels of other immune checkpoint proteins (TIGIT, LAG3, CTLA-4), indicating its role in immune evasion.
Our findings underscore HLA-G's role as a potential prognostic marker and interesting immunotherapeutic target in MIBC. Its impact on immune evasion mechanisms and broad expression, coupled with associations withpoor survival and distinct tumor phenotypes, positions HLA-G as a promising protein for further exploration in developing targeted immunotherapies for MIBC patients.
尿路上皮膀胱癌较为常见,其预后存在差异,受到分子亚型、尿路上皮组织学亚型和免疫微环境的影响。人类白细胞抗原 G(HLA-G)作为一种免疫调节蛋白,在肿瘤组织中呈现明显的膜表达。
我们研究了 241 例肌层浸润性膀胱癌(MIBC)患者中 HLA-G 蛋白的表达情况,阐明了其潜在的临床和生物学意义。评估了蛋白表达水平,并与分子亚型、组织学特征、免疫微环境标志物和生存结局相关联。
HLA-G 高表达与总生存(OS)和疾病特异性生存(DSS)不良相关,且独立于临床病理参数。HLA-G 的表达在分子亚型和尿路上皮组织学亚型之间存在差异,例如基底/鳞状 MIBC 和具有肉瘤样分化的患者中表达水平升高。值得注意的是,在具有免疫逃避微环境(肿瘤细胞 PD-L1 高表达、NK 细胞耗竭、颗粒酶 B(GZMB)/CD8 比值降低、MHC Ⅰ类(MHCI)表达降低)的 MIBC 中,HLA-G 表达增加,这些特点与免疫抑制特征和不良预后相关。此外,HLA-G 与其他免疫检查点蛋白(TIGIT、LAG3、CTLA-4)的水平升高相关,表明其在免疫逃避中的作用。
我们的研究结果强调了 HLA-G 作为 MIBC 潜在预后标志物和有趣的免疫治疗靶点的作用。其对免疫逃避机制的影响及其广泛表达,以及与不良生存和独特肿瘤表型的关联,使 HLA-G 成为 MIBC 患者开发靶向免疫治疗的有前途的蛋白。